InvestWiser

Immunovia publ AB

IMMNOVNasdaq StockholmHealthcareMarket value 33 m SEK
0.03SEK +6.8%
last day · Price as of 18 November 2026

The answer first

Does Immunovia beat the market?

No, Immunovia has not beaten the market over the last year.

Immunovia−88.0%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 0% of Nordic stocks

    • Quality15
    • Value7
    • Trend1

    No. 194 of 195 in healthcare

Max for seven days

Follow Immunovia with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Immunovia

From today, at a price of 0.03 SEK. Write why you follow Immunovia, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Immunovia

Your first answer is free, no account needed.

Do you own Immunovia, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Immunovia and a few more. Free, no card.

Past year against the exchange and Super Stock
Immunovia−89.2%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Immunovia has fallen 88.0% over the past year, including dividends.
  • Overall, Immunovia ranks better than 0% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 99.1%. The price is 100.0% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

0

Quality, value and trend together. Better than 0% of Nordic stocks.

No. 194 of 195 in healthcare

Quality15
The company · Fundamentals: the accounts

Low Weaker accounts than most: low profitability, high debt or uneven results.

No. 177 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.89
  • Asset turnoverSales divided by everything the company owns0.06
  • Return on equityProfit divided by equity−373.7%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value7
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 149 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity3.3
  • P/SPrice divided by sales11.2
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend1
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 193 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−78.4%
  • 6 months−84.3%
  • 9 months−80.6%
  • 12 months−88.0%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−60.6%
3 years, per year
−67.0%
5 years, per year
−75.5%
10 years, per year
−49.9%
Largest fall, 3 years
−99.1%
From a peak to the bottom
From the peak now
−100.0%
How far the price is from the peak
Volatility, 1 year
103.4%
How much the price swings over a year
Beta, 1 year
0.28
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Immunovia

3 funds we follow own Immunovia. The share is how much of the fund the stock makes up.

  • Sweden3

From the funds' latest known holdings.

About Immunovia

Immunovia publ AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 19 employees.

Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

See the full analysis of Immunovia.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market